Brief: Biophytis Requests Pre-Submission Meeting With EMA To Discuss Marketing Authorisation For Treatment Of Covid-19
09/05/2023 07:50
May 9 (Reuters) - Biophytis SA ALBPS.PA :
* HAS REQUESTED A PRE-SUBMISSION MEETING WITH THE EMA FOR
THE
MARKETING AUTHORISATION OF SARCONEOS (BIO101) FOR THE TREATMENT
OF COVID-19
* DEPENDING ON EMA'S RECOMMENDATIONS, WE COULD ENVISION
FILING A
CONDITIONAL MA IN SECOND HALF OF 2023 OR FIRST HALF OF 2024
Source text for Eikon: ID:nEQc2dRCfa
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon